Ireland· IE-PA-EU/1/23/1780/001
Rystiggo 140 mg/ml solution for injection
A rozanolixizumab product containing rozanolixizumab, registered in Ireland by UCB Pharma S.A.. The same ATC class is registered in 4 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Rozanolixizumab is registered in 4 of 19 countries.
Countries holding a registration under ATC L04AG16 (rozanolixizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 3 of them publish a price we can compare per daily dose
Rozanolixizumab · ATC L04AG16
4 / 19 countries
- Belgiumprice
- Ireland
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Rozanolixizumab
- Manufacturer
- UCB Pharma S.A.
- Country
- Ireland (IE)
- ATC code
- L04AG16
- ATC class
- Rozanolixizumab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1780/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rozanolixizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesRYSTIGGOUCB, Inc.
- FranceRYSTIGGO 140 mg/mL, solution injectableUCB PHARMA BELGIQUE
- NetherlandsRystiggo 140 mg/ml oplossing voor injectieUCB Pharma S.A.
- BelgiumRystiggo 140 mg/mlUCB Pharma
- CzechiaRYSTIGGOUCB Pharma SA, Brusel
- United KingdomRystiggo 280mg/2ml solution for injection vialsUCB Pharma Ltd
- Japanロザノリキシズマブ（遺伝子組換え）ユーシービージャパン
- SwitzerlandRystiggo 280 mg/2 ml, solution injectableUCB-Pharma SA
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rystiggo
- Liechtenstein · Rystiggo
- Norway · Rystiggo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/478db6e6-01bc-4b5e-8427-8086a8fccdbc GET /v1/drugs/478db6e6-01bc-4b5e-8427-8086a8fccdbc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"L04AG16"
],
"strength": null,
"pa_number": "EU/1/23/1780/001",
"substances": [
"Rozanolixizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "05/01/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about rozanolixizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.